PROPOFOL EMULSION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

PROPOFOL

Prieinama:

BAXTER CORPORATION

ATC kodas:

N01AX10

INN (Tarptautinis Pavadinimas):

PROPOFOL

Dozė:

10MG

Vaisto forma:

EMULSION

Sudėtis:

PROPOFOL 10MG

Vartojimo būdas:

INTRAVENOUS

Vienetai pakuotėje:

20ML/50ML/100ML

Recepto tipas:

Prescription

Gydymo sritis:

MISCELLANEOUS GENERAL ANESTHETICS

Produkto santrauka:

Active ingredient group (AIG) number: 0121833001; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2024-01-30

Prekės savybės

_PROPOFOL Product Monograph _
_Page 1 of 48_
_ _
PRODUCT MONOGRAPH
PR
PROPOFOL
Propofol Injectable Emulsion, BP
1% w/v
10 mg/mL
Intravenous Emulsion – Anaesthetic - Sedative
Baxter Corporation
7125 Mississauga Road
Mississauga, Ontario
L5N 0C2
Date of Revision:
September 29, 2017
Submission Control No: 207653
_PROPOFOL Product Monograph _
_Page 2 of 48_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
................................................................................26
PHARMACEUTICAL INFORMATION
..........................................................................26
DETAILED PHARMACOLOGY
.....................................................................................27
TOXICOLOGY
..................